Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Methicillin Susceptible Staphylococcus Aureus Infections Pipeline Drugs Market Overview
Methicillin-Susceptible Staphylococcus Aureus (MSSA) is a bacterium that usually causes skin infections, but can also cause pneumonia, and other serious types of infections. The MSSA Infections pipeline drugs market research report provides comprehensive information on the therapeutics under development for MSSA infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.
MSSA Infections Pipeline Drugs Market Segmentation by Targets
Some of the key targets of the MSSA Infections pipeline drugs market are 23S Ribosomal RNA, Bacterial Cell Membrane, Cell Membrane, DNA Gyrase, DNA Topoisomerase IV, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, Penicillin Binding Protein 2a, Peptidoglycan, Teichoic Acid, and Undecaprenyl-Phosphate N-Acetylglucosaminyl 1-Phosphate Transferase.
MSSA Infections Pipeline Drugs Market Analysis, by Targets
For more MSSA Infections pipeline drugs market target insights, download a free report sample
MSSA Infections Pipeline Drugs Market Segmentation by Mechanism of Actions
Some of the key mechanism of actions of the MSSA Infections pipeline drugs market are 23S Ribosomal RNA Inhibitor, Bacterial Cell Membrane Disruptor, Cell Membrane Disruptor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, Penicillin Binding Protein 2a Inhibitor, Peptidoglycan Inhibitor, and Undecaprenyl-Phosphate N-Acetylglucosaminyl 1-Phosphate Transferase Inhibitor.
MSSA Infections Pipeline Drugs Market Analysis, by Mechanism of Actions
For more mechanism of action insights into the MSSA Infections pipeline drugs market, download a free report sample
MSSA Infections Pipeline Drugs Market Segmentation by Routes of Administration
Some of the key routes of administration in the MSSA Infections pipeline drugs market are oral, nasal, intravenous, topical, and inhalational.
MSSA Infections Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into MSSA Infections pipeline drugs market, download a free report sample
MSSA Infections Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the MSSA Infections pipeline drugs market are small molecule, biologic, recombinant protein, and synthetic peptide.
MSSA Infections Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the MSSA Infections pipeline drugs market, download a free report sample
Competitive Landscape
Some of the leading companies in the MSSA Infections pipeline drugs market are BioPlx Microbiomics Pvt Ltd, Basilea Pharmaceutica Ltd, Debiopharm International SA, Destiny Pharma Plc, HyPharm GmbH, LegoChem Biosciences Inc, Naicons Srl, Pharma Holdings AS, Prokaryotics Inc, and Sichuan Saizhuo Pharmaceutical Co Ltd.
MSSA Infections Pipeline Drugs Market Analysis, by Leading Companies
To know more about the companies in the MSSA Infections pipeline drugs market, download a free report sample
MSSA Infections Pipeline Drugs Market Report Overview
Key Targets | 23S Ribosomal RNA, Bacterial Cell Membrane, Cell Membrane, DNA Gyrase, DNA Topoisomerase IV, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, Penicillin Binding Protein 2a, Peptidoglycan, Teichoic Acid, and Undecaprenyl-Phosphate N-Acetylglucosaminyl 1-Phosphate Transferase |
Key Mechanism of Actions | 23S Ribosomal RNA Inhibitor, Bacterial Cell Membrane Disruptor, Cell Membrane Disruptor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, Penicillin Binding Protein 2a Inhibitor, Peptidoglycan Inhibitor, and Undecaprenyl-Phosphate N-Acetylglucosaminyl 1-Phosphate Transferase Inhibitor |
Key Routes of Administration | Oral, Nasal, Intravenous, Topical, and Inhalational |
Key Molecule Types | Small Molecule, Biologic, Recombinant Protein, and Synthetic Peptide |
Leading Companies | BioPlx Microbiomics Pvt Ltd, Basilea Pharmaceutica Ltd, Debiopharm International SA, Destiny Pharma Plc, HyPharm GmbH, LegoChem Biosciences Inc, Naicons Srl, Pharma Holdings AS, Prokaryotics Inc, and Sichuan Saizhuo Pharmaceutical Co Ltd |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease).
- Reviews of pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews of key companies involved in Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- Evaluation of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
BioPlx Microbiomics Pvt Ltd
Debiopharm International SA
Destiny Pharma Plc
HyPharm GmbH
LegoChem Biosciences Inc
Naicons Srl
Pharma Holdings AS
Prokaryotics Inc
Sichuan Saizhuo Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the MSSA Infections pipeline drugs market?
Some of the key targets of the MSSA Infections pipeline drugs market are 23S Ribosomal RNA, Bacterial Cell Membrane, Cell Membrane, DNA Gyrase, DNA Topoisomerase IV, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, Penicillin Binding Protein 2a, Peptidoglycan, Teichoic Acid, and Undecaprenyl-Phosphate N-Acetylglucosaminyl 1-Phosphate Transferase.
-
What are the key mechanism of actions of the MSSA Infections pipeline drugs market?
Some of the key mechanism of actions of the MSSA Infections pipeline drugs market are 23S Ribosomal RNA Inhibitor, Bacterial Cell Membrane Disruptor, Cell Membrane Disruptor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, Penicillin Binding Protein 2a Inhibitor, Peptidoglycan Inhibitor, and Undecaprenyl-Phosphate N-Acetylglucosaminyl 1-Phosphate Transferase Inhibitor.
-
What are the key routes of administration in the MSSA Infections pipeline drugs market?
Some of the key routes of administration in the MSSA Infections pipeline drugs market are oral, nasal, intravenous, topical, and inhalational.
-
What are the key molecule types in the MSSA Infections pipeline drugs market?
The key molecule types in the MSSA Infections pipeline drugs market are small molecule, biologic, recombinant protein, and synthetic peptide.
-
Which are the leading companies in the MSSA Infections pipeline drugs market?
Some of the leading companies in the MSSA Infections pipeline drugs market are BioPlx Microbiomics Pvt Ltd, Basilea Pharmaceutica Ltd, Debiopharm International SA, Destiny Pharma Plc, HyPharm GmbH, LegoChem Biosciences Inc, Naicons Srl, Pharma Holdings AS, Prokaryotics Inc, and Sichuan Saizhuo Pharmaceutical Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.